Gene patents could stand in the way of personalized medicine

Researchers worry that gene patents compromise their ability to tailor treatments to individuals based on their DNA.

One day in December 1995, scientists at Myriad Genetics, a a genetic diagnostics company in Salt Lake City, Utah, were competing in a race to discover the sequences of two genes, BRCA1 and BRCA2, that reveal a woman’s risk of hereditary breast and ovarian cancer.  Sean Tavtigian rushed to his job that day  at Myriad because he knew he could solve the final piece of the puzzle just in time to win Myriad the rights over both genes.

 

 

 

Continue reading… “Gene patents could stand in the way of personalized medicine”

0